Sarepta says FDA delays decision on muscle-wasting disorder drug
February 08, 2016 at 08:45 AM EST
Feb 8 (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had delayed a decision on its lead drug for a rare muscle-wasting disorder.
